MSFrontier

RAM-MS

Randomized autologous hematopoietic stem cell transplantation versus alemtuzumab, cladribine or ocrelizumab for patients with relapsing remitting Multiple Sclerosis
Moved to EU CTIS registryPhase 3Relapsing MS2017-001362-25

What was tested

Treatment tested

  • Cyclophosphamide anhydrous
  • Thymoglobuline®

Compared with

What it measured

Main measures

  • Study Part I:

Other measures (1)

  • The secondary efficacy endpoint for this study is to evaluate the efficacy of the study treatments on the basis of the following endpoints:

Papers

    Loading reviews and guidelines…

    Related trials

    • NET-MS

      Phase 2 · Stopped early

      Stopped early

    • NA

      Phase 2 · Moved to EU CTIS registry

    • StarMS

      Phase 3 · Completed (inferred)

      Result in a paper, not read yet

    • RAM-MS

      Phase 3 · Running, not recruiting

      Still running

    • MOST

      Phase 3 · Stopped early

      Stopped early

    • HiCy

      Phase 2 · Withdrawn

      Stopped early

    History

    1. In scope changed from true to false

    1. Started

      Oct 2017

    Assembled by software from public sources and not checked by people. Each record links to its source. Report an error